Prior Defects Could Sink Auvi-Q Even As EpiPen Prices Soar
Lawmakers and consumers calling for a competitor to challenge Mylan NV in the aftermath of the drugmaker's EpiPen price increases may not have gotten what they wanted with Kaléo Pharma's Auvi-Q,...To view the full article, register now.
Already a subscriber? Click here to view full article